Transdermal delivery of lasofoxifene
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 28, 2002
app pub date -
May 31, 2001
filing date -
Jun 1, 2000
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention to provide methods, pharmaceutical formulations, and devices for the transdermal delivery of 5-substituted-6-cyclic-5,6,7,8,-t-etrahydronaphthalene2-ol compounds ('lasofoxifene' or 'CP-336,156') and pharmaceutically acceptable salts thereof. The invention also provides transdermal compositions of CP-336,156 or its salts dissolved or dispersed in a suitable carrier vehicle, optionally containing permeation enhancers and other excipients. The carrier vehicle may be a pressure sensitive adhesive, polymeric reservoir, or a fluid of controlled viscosity. The carrier vehicle may be contained in a device for purposes of holding the composition against the skin surface. Such devices may be in the form of matrix patches (drug in adhesive) or reservoir patches (drug in a liquid or polymeric reservoir with peripheral, in-line, or over-layed pressure sensitive adhesive). Further provided by this invention are methods for treating pathologies associated with the binding of lasofoxifene with the human estrogen receptor-alpha. For example, the invention formulations and devices are useful to treat or prevent bone loss, obesity, breast cancer, endometriosis, cardiovascular disease and prostatic disease.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully